UK biotech Juvenescence secures over $150m to develop therapies
Endpoints News - 21-May-2025Juvenescence expands pipeline and UAE presence with new funding to tackle age-related diseases
Join the club for FREE to access the whole archive and other member benefits.
Developing therapies against different aging related diseases
Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.
Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life.
By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.
Visit website: https://www.juvlabs.com/
Details last updated 04-May-2019
Juvenescence expands pipeline and UAE presence with new funding to tackle age-related diseases
M42 and Juvenescence join forces to accelerate precision medicine and longevity
Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry
Let's hope their research is either successful for the company or its successors
British entrepreneur, author and philanthropist with interests across a number of industries
Company focused on novel ketone-based therapies for the treatment of heart diseases
10-May-2022
Juvenescence webinar about the latest research and developments on future of longevity investment